G1 Therapeutics (GTHX) PT Raised to $42.00

G1 Therapeutics (NASDAQ:GTHX) had its price objective hoisted by Needham & Company LLC to $42.00 in a report published on Tuesday, The Fly reports. They currently have a buy rating on the stock.

A number of other research analysts have also recently weighed in on the stock. BidaskClub upgraded shares of G1 Therapeutics from a hold rating to a buy rating in a research note on Thursday, March 8th. BTIG Research reiterated a buy rating and issued a $48.00 target price on shares of G1 Therapeutics in a research note on Wednesday, March 7th. JPMorgan Chase & Co. reiterated an overweight rating and issued a $39.00 target price (up from $33.00) on shares of G1 Therapeutics in a research note on Tuesday, March 6th. Cowen reiterated a buy rating on shares of G1 Therapeutics in a research note on Monday, March 5th. Finally, Zacks Investment Research upgraded shares of G1 Therapeutics from a sell rating to a hold rating in a research note on Monday, February 26th. One analyst has rated the stock with a hold rating and six have given a buy rating to the stock. The company presently has an average rating of Buy and an average target price of $38.20.

How to Become a New Pot Stock Millionaire

G1 Therapeutics (NASDAQ:GTHX) opened at $38.73 on Tuesday. G1 Therapeutics has a twelve month low of $12.04 and a twelve month high of $39.29.

G1 Therapeutics (NASDAQ:GTHX) last released its quarterly earnings results on Wednesday, February 21st. The company reported ($0.60) earnings per share for the quarter, missing the consensus estimate of ($0.58) by ($0.02). equities analysts predict that G1 Therapeutics will post -2.47 earnings per share for the current year.

In related news, major shareholder Medimmune Ventures, Inc. sold 200,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The shares were sold at an average price of $19.75, for a total transaction of $3,950,000.00. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, insider Rajesh Malik sold 3,776 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $22.96, for a total transaction of $86,696.96. The disclosure for this sale can be found here. Over the last quarter, insiders sold 217,302 shares of company stock worth $4,314,417.

Several hedge funds have recently made changes to their positions in the stock. Franklin Resources Inc. lifted its stake in shares of G1 Therapeutics by 10.1% during the 4th quarter. Franklin Resources Inc. now owns 1,535,616 shares of the company’s stock valued at $30,467,000 after buying an additional 141,000 shares in the last quarter. BlackRock Inc. lifted its stake in shares of G1 Therapeutics by 113.5% during the 4th quarter. BlackRock Inc. now owns 745,445 shares of the company’s stock valued at $14,790,000 after buying an additional 396,215 shares in the last quarter. Geode Capital Management LLC lifted its stake in shares of G1 Therapeutics by 9.3% during the 4th quarter. Geode Capital Management LLC now owns 94,366 shares of the company’s stock valued at $1,872,000 after buying an additional 8,061 shares in the last quarter. Chartwell Investment Partners LLC lifted its stake in shares of G1 Therapeutics by 5.0% during the 3rd quarter. Chartwell Investment Partners LLC now owns 92,558 shares of the company’s stock valued at $2,303,000 after buying an additional 4,388 shares in the last quarter. Finally, Vanguard Group Inc. purchased a new stake in shares of G1 Therapeutics during the 2nd quarter valued at approximately $1,291,000. Institutional investors own 47.82% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This piece of content was first reported by Markets Daily and is the sole property of of Markets Daily. If you are viewing this piece of content on another domain, it was illegally stolen and reposted in violation of United States and international copyright & trademark laws. The legal version of this piece of content can be read at https://www.themarketsdaily.com/2018/03/14/g1-therapeutics-gthx-pt-raised-to-42-00.html.

G1 Therapeutics Company Profile

G1 Therapeutics, Inc is a United States-based clinical-stage biopharmaceutical company. The Company is engaged in developing small-molecule therapies for the treatment of cancer. Its two clinical-stage candidates are trilaciclib (G1T28) and G1T38, which are potent, selective inhibitors of the validated kinase targets CDK4/6.

The Fly

Analyst Recommendations for G1 Therapeutics (NASDAQ:GTHX)

Receive News & Ratings for G1 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for G1 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply